Dermtech Stock News

DermTech press release (NASDAQ:DMTK): Q4 GAAP EPS of -$0.88 misses by $0.14.Revenue of $3.17M (+51.0% Y/Y) misses by $0.16M.Shares -4.3%.

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported financial results as of and for the quarter and fiscal year ended December 31, 2021. Fourth Quarter and Full Year 2021 Highlights Billable sample volume of approximately 11,780 for the fourth quarter of 2021, a 42% increase compared to approximately 8,300 recorded for the fourth quarter of 2020. Billable sample volume f

DermTech, Inc. (DMTK) delivered earnings and revenue surprises of -20.55% and 5.97%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

DermTech (NASDAQ:DMTK) is scheduled to announce Q4 earnings results on Tuesday, March 1st, after market close.The consensus EPS Estimate is -$0.75 (-56.3% Y/Y) and the consensus…

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that it plans to

It may depend on the underlying premise of what the company is all about.

DermTech Inc (DMTK) shares closed today at 0.7% above its 52 week low of $15.15, giving the company a market cap of $485M. The stock is currently up 3.5% year-to-date, down 49.1% over the past 12 months, and up 68.6% over the past five years. This week, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 0.1%. Trading Activity Trading volume this week was 11.2% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.1. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -444.5% The company's stock price performance over the past 12 months lags the peer average by -292.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

These two stocks could provide life-changing returns in 10 years.

Tygh Capital Management Inc. decreased its position in DermTech, Inc. (NASDAQ:DMTK) by 2.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 155,754 shares of the companys stock after selling 4,617 shares during the quarter. Tygh Capital Management Inc. owned 0.53% of DermTech []

Ausdal Financial Partners Inc. acquired a new position in DermTech, Inc. (NASDAQ:DMTK) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 24,912 shares of the company’s stock, valued at approximately $800,000. Ausdal Financial Partners Inc. owned 0.08% of DermTech at the end […]

DermTech, Inc. (NASDAQ:DMTK)s share price was down 9.6% during mid-day trading on Monday . The company traded as low as $17.01 and last traded at $17.08. Approximately 9,374 shares changed hands during mid-day trading, a decline of 99% from the average daily volume of 773,813 shares. The stock had previously closed at $18.89. A number []

Wall Street brokerages forecast that DermTech, Inc. (NASDAQ:DMTK) will post $3.50 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for DermTechs earnings, with the highest sales estimate coming in at $3.80 million and the lowest estimate coming in at $2.90 million. DermTech reported sales of $2.12 million []

DermTech, Inc. (NASDAQ:DMTK) traded up 9.2% during trading on Friday . The company traded as high as $17.80 and last traded at $17.72. 17,205 shares traded hands during mid-day trading, a decline of 98% from the average session volume of 952,926 shares. The stock had previously closed at $16.22. A number of equities research analysts []